Ruilian Xu

机构：Southern University of Science and Technology, ShenZhen People’s Hospital, Shenzhen Second People's Hospital · ORCID：0000-0002-1396-5915

发表论文 61 篇 · 总被引 1809 次 · h-index 18

代表论文

• Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma (2023 · JAMA · 被引 254)
• Multimodal single cell-resolved spatial proteomics reveal pancreatic tumor heterogeneity (2024 · Nature Communications · 被引 47)
• Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study (2024 · Signal Transduction and Targeted Therapy · 被引 19)
• Robust Capillary- and Micro-Flow Liquid Chromatography–Tandem Mass Spectrometry Methods for High-Throughput Proteome Profiling (2022 · Journal of Proteome Research · 被引 19)
• A real‐world observation on thrombopoietic agents for patients with cancer treatment–induced thrombocytopenia in China: A multicenter, cross‐sectional study (2024 · Cancer · 被引 17)
• Abstract CT248: Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase 2 DESTINY-Lung05 (DL-05) trial (2024 · Cancer Research · 被引 14)